U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Carcinoma

MedGen UID:
854619
•Concept ID:
C3887901
•
Neoplastic Process

Definition

A carcinoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Carcinoma

Professional guidelines

PubMed

Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
An C, Fu Y, Li W, Zuo M, Wu P
Cancer 2023 Jul 15;129(14):2235-2244. Epub 2023 Apr 7 doi: 10.1002/cncr.34764. PMID: 37029486
Extensive-stage small-cell lung cancer: Current management and future directions.
Yu Y, Chen K, Fan Y
Int J Cancer 2023 Jun 1;152(11):2243-2256. Epub 2022 Nov 29 doi: 10.1002/ijc.34346. PMID: 36346100
Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer.
Reed N, Glen H, Gerrard G, Good J, Lei M, Lyon AR, Strachan M, Wadsley J, Newbold K
Clin Oncol (R Coll Radiol) 2020 May;32(5):e145-e153. Epub 2019 Dec 13 doi: 10.1016/j.clon.2019.11.010. PMID: 31843241

Recent clinical studies

Etiology

Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Otsuki S, Hori R, Shinohara S, Kojima T, Tamaki H, Asato R, Kitamura M, Ichimaru K, Kitani Y, Kumabe Y, Honda K, Tsujimura T, Harada H, Ushiro K, Omori K
Auris Nasus Larynx 2022 Oct;49(5):834-844. Epub 2022 Feb 26 doi: 10.1016/j.anl.2022.02.006. PMID: 35232636
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.
Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM
Lancet 2018 Jun 23;391(10139):2525-2536. doi: 10.1016/S0140-6736(18)30996-6. PMID: 29976469
Characteristics and prognosis of patients with thyroglobulin-positive and radioactive iodine whole-body scan-negative differentiated thyroid carcinoma.
Shinohara S, Kikuchi M, Suehiro A, Kishimoto I, Harada H, Hino M, Ishihara T
Jpn J Clin Oncol 2015 May;45(5):427-32. Epub 2015 Feb 26 doi: 10.1093/jjco/hyv021. PMID: 25724214
Intravesical therapy for superficial bladder cancer.
Baselli EC, Greenberg RE
Oncology (Williston Park) 2000 May;14(5):719-29; discussion 729-31, 734, 737. PMID: 10853462
The treated natural history of high risk superficial bladder cancer: 15-year outcome.
Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR
J Urol 1997 Jul;158(1):62-7. doi: 10.1097/00005392-199707000-00017. PMID: 9186324

Diagnosis

Radical cystectomy and orthotopic neobladder in a patient with a preexisting three-components inflatable penile prosthesis.
Rebez G, Runti O, Rizzo M, Trombetta C, Liguori G
Urologia 2023 Aug;90(3):584-586. Epub 2021 Jul 24 doi: 10.1177/03915603211033165. PMID: 34304610
Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?
Schmidbauer J, Lindenau G
Curr Opin Urol 2008 Sep;18(5):504-7. doi: 10.1097/MOU.0b013e32830b86a9. PMID: 18670275
Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.
Hutson TE, Ganapathi R, Elson P, Mekhail T, Olencki T, Budd GT, Bukowski RM
Invest New Drugs 2004 Aug;22(3):277-84. doi: 10.1023/B:DRUG.0000026253.02502.ce. PMID: 15122074
The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC, Steinberg GD
J Urol 2001 Mar;165(3):745-56. PMID: 11176460
Serum calcitonin in small cell carcinoma of the prostate.
Sim SJ, Glassman AB, Ro JY, Lee JJ, Logothetis CJ, Liu FJ
Ann Clin Lab Sci 1996 Nov-Dec;26(6):487-95. PMID: 8908318

Therapy

Extensive-stage small-cell lung cancer: Current management and future directions.
Yu Y, Chen K, Fan Y
Int J Cancer 2023 Jun 1;152(11):2243-2256. Epub 2022 Nov 29 doi: 10.1002/ijc.34346. PMID: 36346100
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.
Ielasi L, Sansone V, Granito A, Benevento F, De Lorenzo S, Tovoli F
Drugs Today (Barc) 2018 Oct;54(10):615-627. doi: 10.1358/dot.2018.54.10.2880176. PMID: 30398482
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.
Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM
Lancet 2018 Jun 23;391(10139):2525-2536. doi: 10.1016/S0140-6736(18)30996-6. PMID: 29976469
Valrubicin in refractory non-muscle invasive bladder cancer.
Sharma P, Zargar-Shoshtari K, Sexton WJ
Expert Rev Anticancer Ther 2015;15(12):1379-87. Epub 2015 Nov 16 doi: 10.1586/14737140.2015.1115350. PMID: 26569509
Intravesical therapy for superficial bladder cancer.
Baselli EC, Greenberg RE
Oncology (Williston Park) 2000 May;14(5):719-29; discussion 729-31, 734, 737. PMID: 10853462

Prognosis

Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Otsuki S, Hori R, Shinohara S, Kojima T, Tamaki H, Asato R, Kitamura M, Ichimaru K, Kitani Y, Kumabe Y, Honda K, Tsujimura T, Harada H, Ushiro K, Omori K
Auris Nasus Larynx 2022 Oct;49(5):834-844. Epub 2022 Feb 26 doi: 10.1016/j.anl.2022.02.006. PMID: 35232636
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.
Ielasi L, Sansone V, Granito A, Benevento F, De Lorenzo S, Tovoli F
Drugs Today (Barc) 2018 Oct;54(10):615-627. doi: 10.1358/dot.2018.54.10.2880176. PMID: 30398482
Characteristics and prognosis of patients with thyroglobulin-positive and radioactive iodine whole-body scan-negative differentiated thyroid carcinoma.
Shinohara S, Kikuchi M, Suehiro A, Kishimoto I, Harada H, Hino M, Ishihara T
Jpn J Clin Oncol 2015 May;45(5):427-32. Epub 2015 Feb 26 doi: 10.1093/jjco/hyv021. PMID: 25724214
The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC, Steinberg GD
J Urol 2001 Mar;165(3):745-56. PMID: 11176460
The treated natural history of high risk superficial bladder cancer: 15-year outcome.
Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR
J Urol 1997 Jul;158(1):62-7. doi: 10.1097/00005392-199707000-00017. PMID: 9186324

Clinical prediction guides

Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Otsuki S, Hori R, Shinohara S, Kojima T, Tamaki H, Asato R, Kitamura M, Ichimaru K, Kitani Y, Kumabe Y, Honda K, Tsujimura T, Harada H, Ushiro K, Omori K
Auris Nasus Larynx 2022 Oct;49(5):834-844. Epub 2022 Feb 26 doi: 10.1016/j.anl.2022.02.006. PMID: 35232636
Expression of liver X receptors in normal and refractory carcinoma tissues of the human lung and pancreas.
Kashiwagi K, Yanagida M, Matsui D, Tanaka M, Sugimoto K, Chen H, Ichikawa-Tomikawa N, Marubashi S, Suzuki H, Chiba H
Histol Histopathol 2018 May;33(5):497-505. Epub 2017 Nov 28 doi: 10.14670/HH-11-949. PMID: 29181837
Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.
Rosevear HM, Lightfoot AJ, Birusingh KK, Maymí JL, Nepple KG, O'Donnell MA; National BCG/Interferon Investigator Group
J Urol 2011 Sep;186(3):817-23. Epub 2011 Jul 23 doi: 10.1016/j.juro.2011.04.073. PMID: 21788050
Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer.
Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M
J Urol 2001 Jun;165(6 Pt 1):1904-7. doi: 10.1097/00005392-200106000-00015. PMID: 11371878
The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC, Steinberg GD
J Urol 2001 Mar;165(3):745-56. PMID: 11176460

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...